Kyrsten Sinema’s Ibogaine Advocacy Playbook: How FDA approval, funding, and coalition building guide her push for access

Ibogaine advocacy drives Kyrsten Sinema’s “playbook” for turning political influence into medical access, based on her personal introduction to ibogaine after a colleague’s reported experience. Sinema frames FDA approval as the central milestone, linking it to subsequent rescheduling and to insurance and CMS coverage so treatment can reach patients in practice, not just in early experiments. She also addresses implementation questions like treatment costs, arguing that an FDA-approved pathway could reduce long term expenses versus chronic or repeated interventions for opioid addiction. The interview also ties ibogaine to broader clinical hopes in neurological disorders, discusses requirements for funding and ongoing research, and highlights the importance of building coalitions while taking Indigenous concerns seriously. It situates this push within Psychedelic Science 2025 and the wider policy environment, including reactions to other psychedelic regulatory outcomes.